The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12 ® in infant colic: A randomised, double blind, placebo-controlled trial

0

Main idea: Supplementation with BB-12 is effective in managing infant colic. The effect could derive from immune and non-immune mechanisms associated with a modulation of gut microbiota structure and function.

Abstract

The pathogenesis of infant colic is poorly defined. Gut microbiota seems to be involved, supporting the potential therapeutic role of probiotics. We tested the probiotic Bifidobacterium animalis subsp. lactis BB-12® (BB-12) on 40 infants with colic for 28 days. The rate of infants with a reduction of $50% of mean daily crying duration was higher in infants treated with BB- 12, starting from the end of the 2nd week.

No infant relapsed when treatment was stopped and stool frequency decreased in both groups, but the effect was significantly higher in the BB-11 group. An increase in Bifids abundance (with a significant correlation with crying time reduction) was also observed.

LEAVE A REPLY

Please enter your comment!
Please enter your name here